ImplaVax; adenovirus vector; adenovirus vector vaccine; BCG vaccine; chickenpox vaccine; chikungunya vaccine; Cytomegalovirus vaccine; dengue vaccine; Ebola vaccine; hepatitis B vaccine; Human immunodeficiency virus vaccine; Human papilloma virus vaccine; immunoglobulin A; immunoglobulin E; immunoglobulin G; influenza vaccine; interleukin 3; interleukin 4; Japanese encephalitis vaccine; malaria vaccine; Meningococcus vaccine; messenger RNA; polysaccharide vaccine; rabies vaccine; respiratory syncytial virus vaccine; RNA vaccine; rotovirus vaccine; unclassified drug; virus like particle vaccine; yellow fever vaccine; Zika virus vaccine; allergic asthma; autoimmune disease; clinical trial (topic); community care; drug delivery system; Ebolavirus; human; immune response; immunogenicity; immunotherapy; Middle East respiratory syndrome; mucus secretion; Mycobacterium tuberculosis; nonhuman; note; pediatrics; phase 1 clinical trial (topic); Plasmodium falciparum; psychological well-being; SARS coronavirus; sequence analysis; severe acute respiratory syndrome; vaccinology; Vector Adjuvant Antigen Standardized Technology; virus attenuation